Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Labrie

Showing results (391-400 of 723) with videos related to

Pageof 73
Sort By:
Basic Life Sciences|January 1, 1974
Mechanism of action of luteinizing hormone-releasing hormoneF Labrie, G Pelletier, P Borgeat, et al.
Biology of Reproduction|June 1, 1980
Effect of an LHRH agonist and hCG on testicular steroidogenesis in the adult ratA Bélanger, L Cusan, C Auclair, et al.
Annales D'Endocrinologie|January 1, 1983
[New antihormone treatment with an antiandrogen and an LHRH agonist in prostate cancer]F Labrie, A Dupont, A Bélanger, et al.
Endocrinology|December 1, 1992
Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormonesJ Couet, J Simard, C Martel, et al.
The Prostate|January 1, 1988
Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamideA Bélanger, M Giasson, J Couture, et al.
Trends in Endocrinology and Metabolism: TEM|November 25, 2000
Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissuesF Labrie, V Luu-The, S X Lin, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1994
Plasma 3 beta-hydroxy-delta 5-steroids in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiencyJ Young, B Couzinet, M Pholsena, et al.
Breast Cancer Research and Treatment|January 1, 1993
Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the ratF Labrie, S Li, A Bélanger, et al.
Journal De Pharmacologie|January 1, 1983
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist]F Labrie, A Dupont, A Belanger, et al.
Biochimie|July 1, 1984
[Epidermal growth factor: structure, location, phosphorylation and regulation of its receptor]R St-Arnaud, J G Chabot, G Pelletier, et al.
Pageof 73

Showing results (391-400 of 723) with videos related to

Sort By:
Pageof 73
Basic Life Sciences|January 1, 1974
Mechanism of action of luteinizing hormone-releasing hormoneF Labrie, G Pelletier, P Borgeat, et al.
Biology of Reproduction|June 1, 1980
Effect of an LHRH agonist and hCG on testicular steroidogenesis in the adult ratA Bélanger, L Cusan, C Auclair, et al.
Annales D'Endocrinologie|January 1, 1983
[New antihormone treatment with an antiandrogen and an LHRH agonist in prostate cancer]F Labrie, A Dupont, A Bélanger, et al.
Endocrinology|December 1, 1992
Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormonesJ Couet, J Simard, C Martel, et al.
The Prostate|January 1, 1988
Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamideA Bélanger, M Giasson, J Couture, et al.
Trends in Endocrinology and Metabolism: TEM|November 25, 2000
Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissuesF Labrie, V Luu-The, S X Lin, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1994
Plasma 3 beta-hydroxy-delta 5-steroids in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiencyJ Young, B Couzinet, M Pholsena, et al.
Breast Cancer Research and Treatment|January 1, 1993
Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the ratF Labrie, S Li, A Bélanger, et al.
Journal De Pharmacologie|January 1, 1983
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist]F Labrie, A Dupont, A Belanger, et al.
Biochimie|July 1, 1984
[Epidermal growth factor: structure, location, phosphorylation and regulation of its receptor]R St-Arnaud, J G Chabot, G Pelletier, et al.
Pageof 73